latest update:
[TrialBase DB]

trial summary · NCT07803952

N-Acetylcysteine in the Management of Spontaneous Bacterial Peritonitis

Adjunctive N-Acetylcysteine in the Management of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis: A Randomized Controlled Trial

Trial record from the TrialBase DB dataset, status RECRUITING, condition SBP - Spontaneous Bacterial Peritonitis, sponsored by Tanta University. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07803952phase PHASE1/PHASE2enrollment 60start 2026-10-25

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Spontaneous bacterial peritonitis (SBP) is one of the most serious infectious complications of liver cirrhosis and ascites. It affects approximately 10-30% of hospitalized patients with decompensated cirrhosis and carries an in-hospital mortality of 20-40% despite appropriate antimicrobial therapy. SBP results from bacterial translocation across the intestinal mucosa together with cirrhosis-associated immune dysfunction, leading to impaired bacterial clearance and exaggerated systemic inflammation. Current international guidelines recommend immediate empirical antibiotic therapy together with intravenous human albumin to reduce the incidence of acute kidney injury (AKI), hepatorenal syndrome, and mortality. Although this strategy has substantially improved outcomes, treatment failure, persistent infection, renal dysfunction, acute-on-chronic liver failure (ACLF), and early mortality remain common, indicating that currently available therapy does not adequately address all pathogenic mechanisms of SBP. Increasing evidence suggests that oxidative stress is a central contributor to the progression of bacterial infections in cirrhosis. Excessive production of reactive oxygen species aggravates hepatocellular injury, endothelial dysfunction, immune dysregulation, and renal impairment, thereby amplifying systemic inflammatory responses during SBP. Consequently, therapeutic strategies targeting oxidative stress may improve host defense while limiting organ injury. N-acetylcysteine (NAC) is a precursor of glutathione and one of the most extensively studied antioxidant agents in …

Source record: https://clinicaltrials.gov/study/NCT07803952

Facts

registry idNCT07803952
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionSBP - Spontaneous Bacterial Peritonitis
sponsorTanta University
sponsor classOTHER
enrollment60
start date2026-10-25
primary completion2027-06-01
completion2027-06-01
results postednot reported

Conditions

  • SBP - Spontaneous Bacterial Peritonitis

Interventions

  • Placebo
  • NAC

Countries

  • Egypt

Intervention types: DRUG

Work with this record